Eli Lilly announces new long term data from study of EBGLYSS

New long-term data show Eli Lilly (LLY) and Company’s EBGLYSS delivered durable skin clearanceandrelief from persistentitch for up to four years for patients with moderate-to-severe atopic dermatitis in an open-label extension study offering once-monthly maintenance injection. Interim findings from the first year of the ADlong Phase 3b study will be presented at the American Academy of Dermatology Annual Meeting, taking place March 27-31 in Denver. In the ADlong study, the majority of patients achieved a high bar of near-complete skin clearance and significant itch relief with up to four years of continuous EBGLYSS treatment. Most patients were on EBGLYSS monotherapy, and 80% achieved results without topical corticosteroids. In addition, 80% achieved these outcomes with EBGLYSS monthly maintenance dosing during the study.